Velsera’s Post

Heading to #ASCO2024? Connect with our clinical leadership team at Booth #11118 for an exclusive demo! Velsera's CGW and clinical-grade Knowledgebase streamline patient treatment decisions by evaluating variant significance, supporting target identification, and generating reports with tailored therapeutic options, saving time and ensuring high-quality outcomes. But wait, there's a whole lot more! Velsera drives new drug discoveries supporting pre-clinical and clinical development, sparking exponential advances in human health. With cutting-edge AI-powered technology, we fuel innovation in healthcare and life sciences, reshaping the industry landscape from R&D to bedside analytics. Our Seven Bridges Platform expedites drug discovery, enhances quality, and reduces costs. Unlock the power of multi-omics data analysis, enhancing precision by more than 50%. From target identification to clinical trials, our solutions support every stage of drug discovery. Schedule a meeting to uncover how we can help you drive the future of precision medicine! https://lnkd.in/gQET4ERf #ASCO24 #Oncology #CancerResearch #EraofVelsera

We need to advance CGT manufacturing to make widespread patient access a reality... Through our LightSpeed Early Access Program (LEAP), we've worked with multiple partners, including CTMC, to gather technical feasibility data that demonstrates IRO®'s ability to provide superior biological performance, minimize batch failures, increase throughput, and scale the impact of life-changing therapies. Here are Jason Bock's, Founder and CEO of CTMC, key insights from his direct experience using the platform: 🧫 IRO® delivered higher CAR+ yields and more efficient transduction (~69% vs ~45%) versus the control. 🧫 Process establishment on IRO® took <5 weeks from kick-off, and met all target release criteria by day 6 across two independent sites. 🧫 Vector copy number remained below the FDA-recommended <5 per transduced cell, meaning IRO® maintained safety and consistency. Read more about IRO®'s technical feasibility data ➡️ https://lnkd.in/eUt_rYfh Interested to see how IRO® could help scale the impact of your therapies? Book a demo today ➡️ https://lnkd.in/eXEXEGZZ #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact CTMC / A joint venture between Resilience + MD Anderson Cancer Center

The Cure(ious) is back! Check out episode one and hear from today's leaders as they share their thoughts on the Future of Health:

If you are thinking to imaging in oncology trials, think about Median. We can deliver services worldwide and thanks to our technologies, can provide enhanced access to information: access images, read markups in real-time. Central imaging providers should be able to provide more than just text and numbers. #clinicaltrials #oncology #imagingtechnology #global

Cooperation across FONS JK Group, a.s. companies   Crucial Synergies for Lipidica: Lipidica greatly benefits from the deep expertise of our sister companies STAPRO and MeDiLa spol s r.o.   MeDiLa's expertise in 🔬 medical laboratory services complements our effort towards accredited medical lab under ISO 15189 and operating as a clinical laboratory facility.   STAPRO's exceptional track record as a leading supplier of medical and laboratory software 💻 for hospitals and other health care providers in Central European markets will push our medical device software “Lipidica 1.0” for processing data generated by lipidomic analysis in pancreatic cancer screening to the next level. #LipidicaSynergy #MEDILALab #StaproSoftware #HealthcareCollaboration   🌟 We bring together business professionals, clinicians, healthcare experts, payers and regulatory authorities, pushing the technology into clinical practice ultimately serving the greater good of society.

If you're in the fields of Molecular Diagnostics or Biopharma, let's connect and discuss how we can drive the future of healthcare together. Your insights could be pivotal in shaping our platform to better serve patients and providers. #healthdata #clinicaltrials #digitaltrials

With the right clinical imaging partner, you can focus on shortening timelines, ensuring operational excellence, and maximizing asset value. Want to know more about Median's best-in-class imaging services for phase I-III oncology #clinicaltrials? Click here: https://lnkd.in/exnA_VMQ #drugdevelopment #iCRO #medicalimaging

Today we are wrapping up another successful edition of the IPF Summit, which brought together over 150 senior decision-makers, academic KOLs, and fibrosis experts to explore and advance pulmonary fibrosis (PF) therapeutics. Key takeaways: • Emerging Biological Insights: New research is reshaping our understanding of PF. • Innovative Models: Groundbreaking models are transforming treatment approaches. • Patient-Centric Focus: Tailoring therapies to diverse patient needs. Thank you to all participants, speakers, and sponsors for your invaluable contributions. Your insights and collaborations are driving PF therapeutics forward. #pulmonaryfibrosis #IPFSummit #innovation #healthcare #research

I would love to see more people improve their health with this. Matomo.myalovea.com Acemannan is being integrated into high levels of medical research! Dr. Renee Hirte has been supervising the research of the plant extract, Acemannan, and says it has exceeded expectations. The goal of this research project is to validate the integrative support it can provide our monoclonal antibody therapy to achieve the best patient outcomes. Additionally, Ron Bruno, Board Director of Netwell Healthshare, says that "Alovéa’s proprietary Acemannan product IMMUN, is the most scientifically-validated technology we were able to find for achieving [our] goals." Acemannan is revolutionizing health, and we're lucky enough to share its benefits with the world. #dailyhealthyhabits #optimizeyourhealth #autoimmunesupport

We are so happy to see Feel Therapeutics highlighted as a leading player in the Digital Biomarkers industry by Research and Markets! 🔎The market of digital biomarkers is expected to grow in the coming years, as the industry of Digital Health and digital solutions continues to evolve. Digital Solutions, such as those provided by #FeelTherapeutics, can collect and track medical information via digital biomarkers, enabling real-time, continuous patient monitoring and facilitating early interventions, by measuring the user’s physiological and behavioral data. Currently, the Industry of Digital Health has begun to integrate digital biomarkers in patient care. The future of digital biomarkers holds potential, bringing the field closer to personalized treatments and a novel approach to patient monitoring and care. 👉Find the research here: https://yhoo.it/3VblyNb #DigitalBiomarkers #DigitalPrecisionMedicine #MentalHealth